Details

Autor(en) / Beteiligte

• Conte, C
• Gallotta, V
• d’Indinosante, M
• Capoluongo, E
• Minucci, A
• De Rose, A
• Ardito, F
• Giuliante, F
• Di Giorgio, A
• Zannoni, GF
• Margreiter, C
• Fagotti, A
• Scambia, G
• Ferrandina, G

Titel

P121 Surgical secondary cytoreduction in recurrent ovarian cancer patients with liver metastasis

Ist Teil von

• International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A134-A134

Ort / Verlag

Oxford: BMJ Publishing Group LTD

Erscheinungsjahr

2019

Beschreibungen/Notizen

• Introduction/BackgroundTo describe accurately the oncological outcomes after hepatic resection (HR) in recurrent ovarian carcinoma (ROC) evaluating clinic-pathological variables and mutational status of BRCA1/2. Although HR is considered a challenging situation in ROC patients, assessment of BRCA1/2 mutational status seems to have a relevant clinical value to guide surgical therapy.MethodologyPatients who underwent HR for ROC at the Catholic University of Rome, between June 2012 and October 2017 were included. Exclusion criteria were represented by extra-abdominal disease and presence of diffuse peritoneal carcinomatosis requiring more than 2 bowel resections. Details relative to HR were collected and BRCA analysis was performed. Predictive factors for of post-relapse progression free survival (PHR-PFS)were assessed by univariate analyses using Cox-proportional hazard regression models.ResultsThirty-four patients undewent HR within secondary cytoreductive surgery (SCS). Six patients (17.6%) presented with hepatic relapse only, while the remaining 28 patients (82.4%) had concomitant extra-hepatic disease. In the whole series, the 3-yr PHR-PFS was 49.1% and the 3-yr progression free survival overall survivalwas 72.9%. Univariate analysis of variables conditioning PHR-PFS showed that only BRCA mutational status played a statistically significant favourable role: the 3-yr PHR-PFS rate was 81.0% in BRCA mutated patient compared to15.2% in wild type ones (p value: 0.001).ConclusionOur clinical analyses suggest that in ROC patients with liver disease the assessment of BRCA mutational status can help to select patients elegible for SCS.DisclosureNothing to disclose.